Stock Update: Merck & Co Inc (NYSE:MRK) – Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting

[Business Wire] – Merck , known as MSD outside the United States and Canada, is proud to be a part of the Blueprint PD-L1 Assay Comparison Project, an important initiative to compare several new diagnostic tests for the immune biomarker PD-L1 in non-small cell lung cancer . Read more on this. Merck & Co. Inc. (MRK) , currently valued at $157.47B, began trading this morning at $56.73. A quick look at the market, the company’s stock traded between $56.22 and $57.38 and has traded between $45.69 and $61.70 over the past 12 months. MRK shares are currently priced at 15.19x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -5.15x forward p/e ratio. And for those looking to make a return holding the stock, the company pays shareholders $1.84 per share annually in dividends, yielding 3.28%. Consensus earnings for the current quarter by the 18 sell-side analysts covering the stock is an estimate of $0.85 per share, which would be $0.00 worse than the year-ago quarter and a $0.03 sequential increase. Furthermore, our analysis shows the full-year EPS estimate to be $3.72, which would be a $0.13 better when compared to the last year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $9.46 Billion. If realized, that would be a 0.42% increase over the year-ago quarter. Recently, Societe Generale Initiated MRK at Buy (Apr 6, 2016). Previously, BofA/Merrill downgraded MRK from Buy to Neutral. Given all the information above, we should disclose to readers that the average price target is $61.20, which is 7.88% above than it opened this morning. See more in (NYSE:MRK) Similar Articles: Market Update (NYSE:MRK): Merck to Present New Data for KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting Company Update (NYSE:MRK): Data on Vericiguat, Investigational Heart Failure Medicine, to be Presented as Late-Breaking Clinical Trial at the 2015 American Heart Association (AHA) Scientific Sessions Company Update: Merck & Co Inc (NYSE:MRK) – Merck’s Pembrolizumab Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.